In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on VistaGen Therapeutics, with a price target of $12.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jason McCarthy’s rating is based on several compelling factors. VistaGen Therapeutics has recently completed its Phase 3 PALISADE-3 study for fasedienol, a treatment for social anxiety disorder, with results expected by the end of 2025. This study, along with the ongoing PALISADE-4 study, represents significant potential catalysts for the company, especially given the prior success of the PALISADE-2 study.
Fasedienol stands out as a promising candidate in the market, particularly after a competitor’s recent failure to meet primary endpoints in a similar study. This positions fasedienol as a potential first-in-class treatment for social anxiety disorder, a significant unmet need. The stock has already seen a substantial increase in value, reflecting investor optimism. Additionally, the company’s strategic plans for commercialization and revenue projections further support the Buy rating, with a 12-month price target set at $12.
In another report released on November 1, William Blair also reiterated a Buy rating on the stock with a $0.00 price target.